Clinical Trial Update: Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

View source ↗

Summary

A completed randomized trial compared an ACE inhibitor strategy with candesartan for the primary treatment of hypertension to reduce cardiovascular events.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Hypertension

Drugs mentioned

• ACE inhibitors
• Atacand (candesartan)

Snippet

Sponsor: AstraZeneca | Conditions: Hypertension, Cardiovascular Disease | Status: COMPLETED